The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women

  1. Nancy R. Cook, ScD;
  2. Julie E. Buring, ScD; and
  3. Paul M Ridker, MD
  1. From Brigham and Women's Hospital, Harvard Medical School, and Harvard School of Public Health, Boston, Massachusetts.
    1. Figure 1.   Risk estimates are provided on a natural log scale and were derived from a Cox regression model using a flexible spline curve. Dotted lines represent 95% CIs.
      View larger version:
        Figure 1.   Risk estimates are provided on a natural log scale and were derived from a Cox regression model using a flexible spline curve. Dotted lines represent 95% CIs. Relative risk (RR) of future cardiovascular events according to baseline high-sensitivity C-reactive protein (hsCRP) levels in the model derivation cohort (n= 15048), adjusted for Framingham covariables.
      • Figure 2. This scoring system is intended as an illustration only. CVD = cardiovascular disease; HDL = high-density lipoprotein; RR = relative risk; SBP = systolic blood pressure. To convert cholesterol values to mmol/L, multiply by 0.02586.
        View larger version:
          Figure 2. This scoring system is intended as an illustration only. CVD = cardiovascular disease; HDL = high-density lipoprotein; RR = relative risk; SBP = systolic blood pressure. To convert cholesterol values to mmol/L, multiply by 0.02586. Cardiovascular point scoring system for women based on Framingham covariables and high-sensitivity C-reactive protein (hsCRP).
        • Figure 3. The model that includes hsCRP shows closer agreement between observed and model-based predicted risk. WHS = Women's Health Study.
          View larger version:
            Figure 3. The model that includes hsCRP shows closer agreement between observed and model-based predicted risk. WHS = Women's Health Study. Calibration curves for risk prediction models without (top) and with (bottom) high-sensitivity C-reactive protein (hsCRP) in the model.

          Responses to this article

          Summary for Patients

          « Previous | Next Article »Table of Contents